drugset / Trial / NCT06735131
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
Phase 2
Recruiting
60 enrolled
Sun Yat-sen University
First Affiliated Hospital Xi'an Jiaotong University · collabWest China Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to explore the best combination patterns of radiotherapy and immunotherapy for advanced triple-negative breast cancer (TNBC).
Timeline
- Start
- 2024-12-20
- Primary completion
- 2026-07
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |
| Background | Carboplatin | Small molecule | 2 unknown | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |